Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.344
Buy
RSI(14)
70.870
Buy
STOCH(KDJ)(9,3,3)
77.127
Buy
ATR(14)
0.881
High Vlolatility
CCI(14)
81.225
Neutral
Williams %R
45.893
Neutral
TRIX(12,20)
2.793
Sell
StochRSI(14)
47.092
Sell
Search
Agenus Inc
AGENAdd to Watchlist
6.600USD
+0.470+7.67%
Close 07-27 16:00（ET）Quotes delayed by 15 min
254.24MMarket Cap
3.20P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+7.67%
5 Days
+32.80%
1 Month
+117.82%
6 Months
+106.90%
Year to Date
+110.19%
1 Year
+10.74%
Key Figures
6.060Open
6.640High
2.78MVolume
3.20P/E TTM
LossP/E Dynamic
--Dividend TTM
7.22%Turnover Ratio
6.130Prev. Close
5.880Low
11.11MTurnover
LossP/E Static
-1.15P/B
0.00%Div Yield TTM
32.32%ROA
7.34052wk High
1.53Volume Ratio
-227.43MNet Profit
38.52MShares
2.0638EPS TTM
1.58Beta
-556.54%ROE
2.71052wk Low
12.40%Amplitude
100.00%Gross Margin
254.24MMarket Cap
19.12Reward/Risk
4.95%Risk Rate
TradingKey Stock Score of Agenus Inc
Currency: USD Updated: 2026-07-27Key Insights
Agenus Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 41 out of 386 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 19.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Agenus Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Agenus Inc Highlights
StrengthsRisks
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Overvalued
The company’s latest PE is 2.97, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 10.91M shares, decreasing 8.15% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 45.64K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 8.47.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
19.000
Target Price
+217.73%
Upside Space
Agenus Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
2
analysts
Buy
Current Rating
19.000
Target Price
+217.73%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Agenus Inc
AGEN
2
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
5.882
Buy
MA10
5.448
Buy
MA20
4.523
Buy
MA50
3.735
Buy
MA100
3.742
Buy
MA200
3.716
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Agenus Inc Info
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Ticker SymbolAGEN
CompanyAgenus Inc
CEOArmen (Garo H)
Websitehttps://agenusbio.com/
Shareholders
Related Instruments
+1.98%
+0.31%
+1.71%
+2.50%
+0.83%
+2.37%
+4.42%
+2.57%
+2.92%
+2.37%
+1.72%
+2.35%
+3.47%
+3.33%
+4.61%
0.00%
+4.24%
+0.60%
+1.34%
-1.93%Popular Instruments
52714.500
+475.500 (+0.91%)
27808.000
-248.000 (-0.88%)
7433.400
+15.000 (+0.20%)
14739.000
-374.000 (-2.48%)
62322.000
-1483.000 (-2.32%)
6299.400
-11.900 (-0.19%)
78.460
-2.877 (-3.54%)
339.990
+3.080 (+0.91%)
196.950
+0.440 (+0.22%)
4028.260
-48.180 (-1.18%)
FAQs
What is the current price of Agenus Inc (AGEN)?
The current price of Agenus Inc (AGEN) is 6.13.
What is the symbol of Agenus Inc?
The ticker symbol of Agenus Inc is AGEN.
What is the 52-week high of Agenus Inc?
The 52-week high of Agenus Inc is 7.34.
What is the 52-week low of Agenus Inc?
The 52-week low of Agenus Inc is 2.71.
What is the market capitalization of Agenus Inc?
The market capitalization of Agenus Inc is 236.33M.
Is Agenus Inc (AGEN) currently rated as Buy, Hold, or Sell?
According to analysts, Agenus Inc (AGEN) has an overall rating of Buy, with a price target of 19.00.
What is the Earnings Per Share (EPS TTM) of Agenus Inc (AGEN)?
The Earnings Per Share (EPS TTM) of Agenus Inc (AGEN) is -0.00.